Human Genome Sciences

  • What GlaxoSmithKline's Latest Move Means for You

    By Jordo Bivona - July 25, 2012 | Tickers: AMLN, AZN, BMY, GSK, HGSI

    GlaxoSmithKline (NYSE: GSK) recently announced the completion of its acquisition of Human Genome Sciences (NASDAQ: HGSI) for approximately $3 billion. The acquisition will be completed at $14.25 a share, including cash and debt, valuing the target at $3.6 billion, a nearly 100% premium over Human Genome Science's stock price on April 18 when GlaxoSmithKline's intention was first announced. Aside from the obvious implications for the two more »

  • Biotech Dangers

    By AnnaLisa Kraft - July 11, 2012 | Tickers: DNDN, HGSI, PIP, QCOR, SIGA

    There were several biotech investing dangers I wanted to discuss in greater depth since I wrote the first piece. Two things in particular I wanted to warn potential biotech investors about are the threat of class action lawsuits on behalf of their fellow shareholders and pharma vs pharma suits as well as short pressure.

    Shareholder vs Biotech

    According to a lawyer friend there are literally hundreds of firms that troll more »

  • Driven By Speculators?

    By Jordo Bivona - July 11, 2012 | Tickers: ABT, GSK, HGSI

    At this point in time, I believe GlaxoSmithKline (NYSE: GSK) is more of a speculative investment. In this article, I will explain why investors should wait for dips for optimum entry points, while shareholders should hold for an extended period and watch each earnings report closely. Competition is increasing in the industry while there are a number of macroeconomic dynamics that are creating headwinds for GlaxoSmithKline. There are a number more »

  • Amylin Deal Signals Diabetes Space is Hot

    By Tony Daltorio - July 6, 2012 | Tickers: AMLN, AZN, BMY, GSK, HGSI

    The bidding war for Amylin Pharmaceuticals (NASDAQ: AMLN) is over with a successful joint bid for the company by Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca PLC ADR (NYSE: AZN). In a two-part transaction, Bristol-Myers will first pay $5.3 billion cash to Amylin stockholders. It will also assume debt and royalties payable to Amylin's partner Eli Lilly for another $1.7 billion. 

    But then Bristol-Myers will fold the company more »

  • Lower Price of Benlysta Could Boost HGSI

    By Jordo Bivona - June 11, 2012 | Tickers: AMGN, BIIB, GSK, HGSI

    Human Genome Sciences (NASDAQ: HGSI), is a biotechnology company that develops sale-able drug treatments based on its genetic research.  The company first came to notoriety in the late-1990’s with its effort to map the entire human genetic code.  With a 52-week high above $28, a 52-week low under $7, and a current price around $15, it’s safe to say that the stock has been relatively turbulent. 

    In April more »

  • New Developments in Pharma Stocks

    By Meena Krishnamsetty - April 26, 2012 | Tickers: AZN, LLY, GSK, HGSI

    We have previously voiced concerns over the future of AstraZeneca (NYSE: AZN), in particular its lackluster pipeline (read more on high dividend pharma stocks). Based on the company’s situation, we anticipated that it would engage in M&A activity to bolster its pipeline. Yesterday’s announcement of AZN’s $1.3 billion acquisition of Ardea Biosciences falls in line with our speculation. The acquisition adds the Phase III gout more »

  • Achillion: A Compelling 'Buy' Candidate Now

    By Maxwell Fisher - April 16, 2012 | Tickers: ACHN, DNDN, HGSI

    There are numerous biotech stocks out there and the key to smart investing is finding one that is a good value. This might not be the cheapest available and it might not be the overall best, but it will be a solid earner for the money you invest. What I always tell investors searching for a good value is to find mid-price companies with strong pipelines. In general, avoid companies more »

  • Keryx: A Biotech For Aggressive Investors

    By Maxwell Fisher - March 30, 2012 | Tickers: DNDN, HGSI, JNJ, KERX

    Keryx Pharmaceuicals (NASDAQ: KERX) is a biotechnology company involved in the development of pharmaceutical products for treating life-threatening diseases. Currently, its main focus is on drugs that treat renal disease and cancer. It has two drugs in phase 3 trials: Zerenex (ferric citrate), which is an oral, iron-based compound used to treat patients with end-stage renal disease, and KRX-0401 (perifosine), an oral anti-cancer agent intended to treat advanced colorectal cancer more »

  • Looking For Solid Science in Biotech

    By Streetwise Reports - March 5, 2012 | Tickers: AZN, AVNR, GILD, HGSI, NPSP, VRTX

    George S. Mack, The Life Sciences Report

     Solid ideas in biotech come from solid research.

    I first spoke with Analyst Carol Werther in early 1999 when I was preparing to write about Immunex which had developed Enbrel (etanercept) for rheumatoid arthritis (RA). The product had just been approved by the FDA in November 1998, and it held the distinction of being the first in a new class of anti-tumor necrosis more »

  • Can These Biotechs Make You Money In 2012?

    By Robert Fisher - January 14, 2012 | Tickers: ARIA, DNDN, HGSI, ILMN, MNKD

    The biotech group is among the largest in the market in terms of the number of companies. They trade with perhaps the highest volatility in the market and move heavily on optimism of future successful drugs. The five biotech stocks on my radar today are Dendreon Corp. (NASDAQ: DNDN), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Human Genome Sciences (NASDAQ: HGSI), Illumina Inc. (NASDAQ: ILMN) and MannKind Corp. (NASDAQ: MNKD). The outlook more »

  • J.P. Morgan Healthcare Conference Schedule: Day One

    By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ

    The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.

    I will be following (and covering) the novel therapeutic companies that have caught my eye. VIVUS (NASDAQ: VVUSmore »)